Vydané akcie společnosti Edesa Biotech

Jaká je hodnota metriky Vydané akcie společnosti Edesa Biotech?

Hodnota metriky Vydané akcie společnosti Edesa Biotech, Inc. je 18.154M

Jaká je definice metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všech akcií společnosti nebo finančních aktiv, které byly autorizované, vydané a koupené investory a jsou jimi vlastněné.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Edesa Biotech

Čemu se věnuje společnost Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou vydané akcie podobnou společnosti Edesa Biotech



  • Hodnota metriky Vydané akcie společnosti Zhongchao je 18.103M
  • Hodnota metriky Vydané akcie společnosti New Destiny Mining je 18.106M
  • Hodnota metriky Vydané akcie společnosti Gulfport je 18.107M
  • Hodnota metriky Vydané akcie společnosti Aptose Biosciences Inc je 18.109M
  • Hodnota metriky Vydané akcie společnosti Vigil Health Solutions je 18.128M
  • Hodnota metriky Vydané akcie společnosti Orca je 18.151M
  • Hodnota metriky Vydané akcie společnosti Edesa Biotech je 18.154M
  • Hodnota metriky Vydané akcie společnosti New Home Inc je 18.161M
  • Hodnota metriky Vydané akcie společnosti Career Point je 18.163M
  • Hodnota metriky Vydané akcie společnosti Phio Pharmaceuticals je 18.164M
  • Hodnota metriky Vydané akcie společnosti Vasta Platform je 18.169M
  • Hodnota metriky Vydané akcie společnosti Cosmo Films je 18.173M
  • Hodnota metriky Vydané akcie společnosti V-Mart Retail je 18.174M